06 September 2011

LONGWOODS PUBLISHING ,: ADVERTISED JOBS

Featured Careers
See the entire list of leadership and nursing careers at Jobs.Longwoods.com
Patient Care Manager, Inpatient Surgery - Lakeridge Health, Oshawa, ON
Quality and Compliance Specialist - Lakeridge Health, Oshawa, ON
Quality Practice Leader - Resident Assessment Instrument (RAI) - Bethany Care Society, Calgary, AB
Director, Pharmacy Services - Humber River Regional Hospital, Downsview, ON
Sales Director - NRC Picker Canada, Markham, ON
Executive Director - Burlington Family Health Team, Burlington, ON
Director of Human Resources - City of Kitchener, Kitchener, ON
Director of Operations - ParaMed,, Markham, ON
Vice-President, Patient Care and Chief Nursing Executive - Hotel Dieu Hospital, Windsor, ON
Director, Policy and Research - Council of Academic Hospitals of Ontario Toronto, ON
President and CEO - Women’s College Hospital Foundation, Toronto, ON
Policy Analyst - Toronto Academic Health Science Network Toronto, ON
Vice President, Transplant - Trillium Gift of Life Network, Toronto, ON
Vice-President of Nursing - Hamad Medical Corporation (HMC) Doha, Qatar
Benefits Consultant - Ontario Hospital Association, Toronto, ON
Manager, Organizational Development - Bridgepoint Health, Toronto, ON
Medical Advisor - Workers' Compensation Board of Nova Scotia, Halifax, NS
Senior Analyst, Corporate Performance and Process Improvement - Bridgepoint Health, Toronto, ON
Editor-in-Chief - Canadian Medical Association Journal, Ottawa, ON
Chief of Staff and Psychiatrist-in-Chief - Waypoint Centre for Mental Health Care, Penetanguishene, ON
Vice President of Program Development - The Abilities Centre, Toronto, ON
Chief Executive Officer - The Atikokan General Hospital. Atikokan, ON
President and Chief Executive Officer - Campbellford Memorial Hospital, Campbellford, ON
For more information or to post a position go to Jobs.Longwoods.com or email Susan Hale

02 September 2011

CELL: Yale University ADIPOCYTE LINEAGE CELLS may alter function EPITHELIAL STEM CELL

true

Cell Career Network

Huntingdon, PA
Juniata College
Houston, TX
Baylor College of Medicine
Montréal, Québec
Institut de recherches cliniques de Montréal
Click here to find out more!

Adipocyte Lineage Cells Contribute to the Skin Stem Cell Niche to Drive Hair Cycling

  To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.
Cell, Volume 146, Issue 5, 761-771, 2 September 2011
Copyright 2011 Elsevier Inc. All rights reserved.
10.1016/j.cell.2011.07.019

Authors

  • Highlights
  • Resident skin adipocytes regenerate de novo in parallel with the hair cycle
  • Immature adipocytes are necessary and sufficient for hair follicle regeneration
  • Immature adipocytes express PDGF ligands to promote hair regeneration

Summary

In mammalian skin, multiple types of resident cells are required to create a functional tissue and support tissue homeostasis and regeneration. The cells that compose the epithelial stem cell niche for skin homeostasis and regeneration are not well defined. Here, we identify adipose precursor cells within the skin and demonstrate that their dynamic regeneration parallels the activation of skin stem cells. Functional analysis of adipocyte lineage cells in mice with defects in adipogenesis and in transplantation experiments revealed that intradermal adipocyte lineage cells are necessary and sufficient to drive follicular stem cell activation. Furthermore, we implicate PDGF expression by immature adipocyte cells in the regulation of follicular stem cell activity. These data highlight adipogenic cells as skin niche cells that positively regulate skin stem cell activity, and suggest that adipocyte lineage cells may alter epithelial stem cell function clinically.

01 September 2011

12th DENGUE COURSE: 8-19 Aug.,2011. HAVANA

Under the auspices of
'Pedro Kourí' Tropical Medicine Institute (IPK)
Ministry of Public Health of the Republic of Cuba (MINSAP)
Pan American Health Organization (PAHO)
 
WHO Special Program for Research and Training  in Tropical Diseases (TDR)
World Health Organization (WHO)

A global pandemic of dengue fever, a mosquito-borne viral disease, started during World War II, intensifying during the 70’s. Since then, the prevalence of dengue fever as well as the life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) has increased exponentially, with approximately 2.5 billion people at risk, about 50 million cases and 250-500 000 severe cases occur annually. At present, dengue is reported in Southeast Asia, the Western Pacific, and in the American and the Mediterranean regions. In the last years, an increased number of epidemics are being reported in Africa.
In this context, the PAHO/WHO Collaborating Center for the Study of Dengue and its Vector of the ‘Pedro Kourí’’ Tropical Medicine Institute (IPK), Havana, Cuba, together with the Cuban Ministry of Public Health, the Pan American Health Organization (PAHO), the World Health Organization (WHO) and the WHO Special Program for Research and Training in Tropical Diseases (TDR) organize, since 1987, their biannual International Dengue Course.
This 12th edition of the Course, covering 24 years (1987-2011) of work, will allow to strengthening capacities in dengue control and prevention, taking into account the most current and advanced knowledge and experiences.  

The Course’s objective is that participants -physicians, virologists, immunologists, sociologists, epidemiologists, entomologists, and health managers, among others interested in this field, along with many professors from several prestigious national and international institutions, may have the opportunity to debate on the most relevant and updated aspects of this disease and its control.

Through theoretical and practical sessions, the main aspects related to dengue will be covered: dengue epidemiology, clinical management, diagnosis, virology and immunology, vector control, environmental risk factors and community participation. Important aspects to be discussed are trends of dengue at global level, impact of climate change, new dengue clinical classification, opportunities for diagnosis, impact of virus diversity, immunogenetics, complexity of dengue immunity and pathogenesis, dengue vaccines, new highlights and challenges, integrated surveillance and control, difficulties, options, challenges, economic burden, new options for control, insecticide resistance, the environment, health systems and dengue, among others. Within the framework of the course, the new global initiatives for dengue and the experiences of several countries and geographical regions will be showed.  
In the first week, general lectures as well as round tables and symposia on the topics of clinic, emergency response, diagnostic, pathogenesis, vaccines, antiviral drugs, integrated control and chikungunya and other emergent arboviruses are also scheduled. In addition several expert meetings will be organized.
General topics to be covered
  • Dengue, current epidemiological situation.
  • Global initiatives
  • Integrated dengue surveillance
  • Viral genome and structure
  • Viral replication.
  • Clinical picture and pathology. Clinical management
  • WHO dengue clinical classification.
  • PAHO/WHO Dengue Guidelines for clinical management
  • Dengue diagnostic and laboratory surveillance
  • Immune response to dengue. Protection or pathogenesis?
  • Antibody dependent enhancement (ADE).
  • Genetic host susceptibility to dengue illness
  • Pathogenesis and physiopathology  
  • Animal models for dengue study
  • Dengue vaccine candidates. Vaccination challenges
  • Drugs for dengue treatment
  • Ecology of Aedes aegypti  
  • Vector dynamic for dengue transmission
  • Entomological surveillance of Aedes aegyti.
  • Chemical and biological vector control methods.
  • Mechanisms of Insecticide Resistance  
  • Social aspects in dengue
  • Mathematical models for dengue transmission study
  • Integral Strategy (EGI) for dengue prevention and control
  • Ecobiosystem approach for dengue control and prevention
  • The community role in dengue control.  
  • Cost/effectivity of dengue control activities
  • Emergency management for outbreak control
  • Cuban experience: surveillance and control
  • Environment, climate change and dengue
  • Chikungunya and other emergent arboviruses
     

The Course is structured in two sections: theoretical and practical. The theoretical section will be conducted during the first week and the practical section during the second week.
In the theoretical section, general lectures, round tables and symposia have been scheduled.
In the practical section, participants will gather in several groups, according to their interests: clinical care, entomology, community participation, virology and epidemiology. 
Participants will have opportunity to present their results in a poster session scheduled in the first week. Poster characteristics: 94cm wide X 140cm high (vertical position).
 

Foreign
Olivia  Brathwaite, PAHO/WHO
Arachu Castro, Harvard University, USA
Laurant Coudeville, Sanofi Pasteur
Derek Cummings, Johns Hopkins Bloomberg School of Public Health, Baltimore, USALuiz Jacintho Da Silva, DVI
Delia Enria, J.A. Maiztegui Institute, Argentina
Carlos Espinal, Sanofi Pasteur
Scott B. Halstead, PDVI
Eva Harris, Berkeley University, USA

Kenji Hirayama, Institute of Tropical Medicine, Nagasaki, Japan
Joachim Hombach, IVR, WHO
Olaf Horstick, German International Co-operation, GIZ
Axel Kroeger, TDR/WHO
Jean Lang, Sanofi Pasteur
Julien Lescar, Novartis Institute for Tropical Diseases, Singapore
Audrey Lenhart, Liverpool School Tropical Medicine, UK
Linda Lloyd, San Diego, California, USARamon Martinez, PAHO/WHO
Romeo Montoya, PAHO/WHO
Amy Morrison,
University of California Davis, California, USAFernando Noriega, Sanofi Pasteur
Jorge Osorio, Wisconsin University, USA
Rosanna Peeling, London School Tropical Medicine, UK
José L. San Martín, PAHO/WHO
Siew Pheng, Novartis Institute for Tropical Diseases, Singapore
Chanditha Hapurachchi
, Environmental Health Institute, SingaporeGavin Screaton, Imperial College, UK
David Severson, Notredame University, USA
Frederic Tangy, Institute Pasteur, France
Patrick Van Der Stuyft,
Institute of Tropical Medicine, Antwerp, Belgium
Veerle Vanlerberghe,
Institute of Tropical Medicine, Antwerp, Belgium
Paul Young,
University of Queensland, Brisbane, Australia

Cubans
Gustavo Kourí, María G. Guzmán, Eric Martínez, Susana Vázquez, María E. Toledo, Juan Bisset, , Delfina Rosario, Maritza Pupo,
Virginia Capó, Mayling Alvarez, Rosmari Rodríguez-Roche,
Ana B. Pérez, Beatriz Sierra, Gisel García, Liset Sánchez,
Omar Fuentes, Magdalena Rodríguez, Alberto Baly,
Miriam Concepción Rojas, Ana M. Ibarra, Juan V. Cangas, 
Otto Pelaez, Angel M Alvarez
, Osvaldo Castro, among other prestigious professors and collaborators (IPK, INHEM, Ministry of Health, Cuba).

SANOFI PASTEUR in phase III of DENGUE VACCINE

Vice President, Communications Sanofi Pasteur: Alain Bernal Vice President, Media and Scientific Communications: Pascal Barollier +33 4 3737 5038 Vice President, U.S. Communications: Len Lavenda +1 570 957 0717 Sanofi Pasteur S.A. Headquarters - 2, avenue Pont Pasteur - F-69367 Lyon cedex 07 - France Sanofi Pasteur Inc. – Discovery Drive – Swiftwater, PA 18370-0187 – USA – www.sanofipasteur.com
CHANGING THE LIVES OF MILLIONS
1 LEADING DENGUE VACCINE CANDIDATE
A GLOBAL PUBLIC HEALTH CHALLENGE
There is no specific treatment and vaccination is the only efficient means of fighting against dengue fever.
Sanofi Pasteur, a world leader in vaccines, has taken on the challenge of providing the first dengue vaccine for individuals living in endemic areas and developing countries as well as for those who plan to travel to those areas.
Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat for almost half of the world’s population(1).
Dengue fever occurs mostly in tropical and subtropical countries (2) and is spreading to new parts of the globe each year. Many factors contribute to the spreading of dengue fever, including urbanization and increased travel which facilitate the dissemination and the circulation of this disease.
Source: WHO, Global Health Observatory Map Gallery, available on: http://gamapserver.who.int/mapLibrary/Files/Maps/Global_DengueTransmission_ITHRiskMap.png
Key figures(1,3)…
An Aedes Aegypti mosquito which
spreads dengue
2
60 YEARS OF SCIENTIFIC ENDEAVOR
From early scientific discoveries ….
1944:
1944-45:
1956:
1970-1980:
isolation and identification of the 1st serotype (in Hawaii, DEN1) and 2nd serotype (in N.Guinea, DEN2) by Sabin and Schelsinger(4). first monovalent dengue vaccine, a live attenuated vaccine (LAV) DEN1, developed by Sabin and Schelsinger(4). isolation and identification of the 3rd serotype (DEN3) and 4th serotype (DEN4) by W. Hammon(5). development of a tetravalent LAV DEN1, DEN2, DEN3, DEN4, by Pr Natth Bhamarapravati at the Mahidol University (Bangkok - Thailand). At this point, data from clinical investigations conducted in Thailand showed promise for a tetravalent dengue vaccine(6).
Vice President, Communications Sanofi Pasteur: Alain Bernal Vice President, Media and Scientific Communications: Pascal Barollier +33 4 3737 5038 Vice President, U.S. Communications: Len Lavenda +1 570 957 0717 Sanofi Pasteur S.A. Headquarters - 2, avenue Pont Pasteur - F-69367 Lyon cedex 07 - France Sanofi Pasteur Inc. – Discovery Drive – Swiftwater, PA 18370-0187 – USA – www.sanofipasteur.com
• 2.5 billion people at risk in over 100 countries
• Estimated 220 million people infected annually
• 2 million, mostly children, develop dengue hemorrhagic fever, a severe form of the disease  

31 August 2011

GP Behnaz YAZDANFAR facing 60 day CPSO "Court" costs of $219,000.

From  Toronto SUN

 A Toronto doctor has been found guilty of professional misconduct and deemed “incompetent” following the death of one of her patients and botched procedures performed on others.
Dr. Behnaz Yazdanfar “failed to maintain the standard of practice” and was “unprofessional” while practising cosmetic surgery from 2005 to 2008, the College of Physicians and Surgeons of Ontario stated Wednesday following a high-profile disciplinary hearing in two years ago.
Patient Krista Stryland, 32, died following stomach-reduction surgery at Yazdanfar’s North York clinic in September 2007. During Yazdanfar’s 2009 hearing, a plastic surgeon testified that Stryland “was bleeding so profusely from multiple puncture wounds” that her heart stopped.
A paramedic who worked on Stryland testified at the hearing that Yazdanfar and her anesthesiologist, Dr. Bruce Liberman, waited too long to call 911.
It was also heard that Liberman, who was taking care of Stryland following her surgery, left the recovery room to get a snack while Stryland lay with weakening vital signs.
Liberman was also found guilty Wednesday of misconduct and “disgraceful” performance.
Also mentioned in Wednesday’s decision was former Yazdanfar patient Francine Mendelson, 66, who filed a complaint with the CPSO after learning of Stryland’s death.
Mendelson said in July 2009 that following her $7,000 liposuction at Yazdanfar’s clinic, she was bleeding so badly after returning home, her husband had to cover their bed with garbage bags.
The CPSO found that Yazdanfar failed to make “appropriate treatment decisions” and “recognize and...manage complications,” and called the online advertising for her clinic “deceptive.”
Yazdanfar has been under an order by the College not perform surgeries since the completion of her disciplinary hearing.
Yazdanfar was a family doctor after graduating from the University of Ottawa in 1994. She began focusing on cosmetic surgery in 2000.
A penalty hearing is pending.
terry.davidson@sunmedia.ca

GP Behnaz YAZDANFAR found GUILTY. Will CPSO REGISTRAR GERACE RESIGN?

Complaint against liposuction doctor was a perceptive warning

Christie Blatchford | Columnist profile | E-mail
From Wednesday's Globe and Mail
Click Here
More than a year before a young woman died after liposuction at a Toronto cosmetic clinic, the College of Physicians and Surgeons of Ontario dismissed a complaint against the doctor who performed the procedure.
And ironically, the college, which is now prosecuting Behnaz Yazdanfar for alleged incompetence – the hearing resumes next week – at that time pronounced her properly trained and qualified.
Krista Stryland, a 32-year-old realtor, died Sept. 20, 2007, from complications after having extensive liposuction to remove fat.
But on March 16, 2006, Terry Polevoy, a Waterloo, Ont. doctor who runs a skin care clinic and is also a medical and social activist, lodged a complaint about Dr. Yazdanfar and her Toronto Cosmetic Clinic.
One prong of the complaint focused on the doctor’s advertising – in particular, an ad which suggested cosmetic surgery fell under the plastic surgery umbrella, an apparent contravention of the college rule that only board-certified plastic surgeons can use the term – but the second questioned her “qualifications to perform invasive surgical procedures without approved surgical training and certification.”
Dr. Polevoy had stumbled across Dr. Yazdanfar’s two-page ad in a cosmetic magazine called Elevate, which a staffer in his office had brought in. He did a quick check of Dr. Yazdanfar’s background – she’s a family doctor who switched to cosmetic surgery – and launched his complaint.
It’s considered unusual for one doctor to complain about another to the college; most complaints come from former patients or concerned members of the public.
The matter was referred to the college’s complaints committee, which conducted an investigation of sorts, found Dr. Yazdanfar had completed a “preceptorship,” a kind of internship, attended other workshops and the like, and had abided by all college policies.
Saying it didn’t “share” Dr. Polevoy’s concerns, the committee concluded Dr. Yazdanfar “was qualified to perform the cosmetic procedures at issue” and didn’t refer the complaint on for a disciplinary hearing – effectively putting a stop to it.
But in November, 2006, after the original decision was released, Dr. Polevoy promptly appealed it to the Health Professions Appeal and Review Board, a tribunal of government appointees.
Describing himself as “shocked and amazed” by the committee decision, Dr. Polevoy raised additional concerns about freestanding surgical centres such as Dr. Yazdanfar’s clinic, which at the time were not required to be licensed, registered or inspected.
It was a prescient warning.
About 11 months later, that issue would be raised in Ms. Stryland’s death – she “crashed” shortly after the surgery and was revived, but there was a significant delay in calling 911 and getting her to hospital.
It took the health board about 16 months to hear Dr. Polevoy’s appeal, and when he appeared in person to argue that the committee decision was flawed and should be overturned, Ms. Stryland was dead.
Her name isn’t mentioned in the board’s March 23, 2009, decision.
Dr. Polevoy told the health board he was alarmed when he read Dr. Yazdanfar’s ads and realized she was a family doctor who hadn’t completed any surgical residency training and was “performing such invasive cosmetic operations as breast augmentation surgery.”
But as Dr. Yazdanfar’s lawyer argued, there is no legislation or policy in Ontario prohibiting doctors from performing cosmetic surgical procedures – a festering issue for plastic surgeons, who must meet rigorous licensing and training standards to perform the same procedures.
Dr. Polevoy was also critical of the quality of the original investigation done by the college, suggesting it was cursory.
But the board decided the investigation was adequate and the decision reasonable.
Dr. Yazdanfar’s hearing on charges of professional misconduct and incompetence resumes next week, as does that of an anesthetist, Bruce Liberman, who worked with Dr. Yazdanfar at the clinic and faces similar charges in connection with Ms. Stryland’s death.
But where the Ontario Divisional Court found that Dr. Liberman’s work had passed a detailed independent review and thus he shouldn’t have limitations imposed pending the college decision, another panel of the same court said that in a review of her practice, Dr. Yazdanfar hadn’t fared nearly so well.
Of 40 randomly selected files, 29 of which involved liposuction, the review found that Dr. Yazdanfar had exceeded all guidelines by removing far too much fat in a single go from her patients.
In one case, the court said in a June 5, 2009, decision, “a patient had seven litres of just fat removed and she was then discharged after surgery, unaccompanied, in a taxi.”
The file review, the court said, “illustrates serious safety concerns,” and upheld the restrictions the college had imposed almost 20 months after Ms. Stryland’s death.
Until the charges are resolved, Dr. Yazdanfar can’t perform surgery and can work only as a surgical assistant, under supervision

29 August 2011

LAHORE : DENGUE FEVER 1000 cases.

Eid congregation venues yet to be fumigated

LAHORE, Aug 28: As dengue fever patients have touched the 1,000 mark in Lahore alone, the Punjab health department and city district government of Lahore are yet to fumigate a number of parks where Eid congregations are to be held, it is learnt.
Large-scale movement of people to and from the Punjab capital may also worsen the situation as carriers of the disease can be the major risk for the spread of the dengue virus.
The respective authorities already struggling hard to prevent dengue spread have reportedly ignored bus, train and airline terminals from where massive travelling is expected ahead of Eid.
The health and medical experts believe that these places may become potential threats to the health of a large number of passengers.
They say especially goods, luggage and other articles in public transport may cause spread of dengue mosquitoes if timely and effective fumigation or spray was delayed prior to Eid. Similarly, the CDGL has no plan so far for fumigation at parks and open places where Eid prayers are to be offered in the morning. Any negligence in this regard may pose a threat to the health of scores of faithful as the Aedes Agypti is active in the morning and in the evening.
According to a source, efforts to control dengue fever in the city also affected when differences developed between Lahore Executive District Officer (EDO) Dr Umer Farooq Baloch and the Punjab health department officials over the number of patients tested positive for dengue virus.
In a recent meeting, Dr Umer Baloch has raised an objection to the reporting mechanism devised by the Punjab Directorate General Health Services to collect data on dengue fever patients in the city.
The source said the health EDO claimed in the meeting that some health department officials had reported around 950 dengue patients in the city while the actual number was not more than 450.
When contacted Punjab Health Director-General Chaudnry Muhammad Aslam said there was no separate plan for places like Lorry Adda, railway station, Niazi Bus Stand etc. for fumigation.
He said instructions had already been issued to the CDGL officials for fumigation at such public places besides schools, public toilets, marriage halls, etc. To a question about the differences over the number of patients, he said the health department officials collected data from public and private hospitals of the city and later forward it to the health EDO.
He said the EDO later finalised the dengue cases after verifying them from the respective health facility. During verification process, he said, the EDO expressed his doubt about some dengue cases owing to duplication and incomplete particulars of patients.
He, however, said there was no difference over the number of dengue fever patients between the health department officials.
Dr Umer Farooq told Dawn that some 450 people were diagnosed with dengue in the city so far.
He said some health department officials had entered names of several patients twice in the final list of confirmed dengue patients besides mentioning some of those patients whose particulars were incomplete.